![BlakeSmithJ's tweet photo. 📈 [Today's Stock Forecast]
Stock Code: $CWH
Buy Price: $17.23-17.82
Target Price: $25-35
Stop Loss: $12
Holding Period: 20-30 Days
Latest Updates: In the first quarter of 2025, $CWH achieved revenue of $1.41 billion, a year-on-year increase of 3.6%, but failed to meet Wall Street expectations (expected to be $1.45 billion). Non-GAAP loss per share was $0.16, better than analysts' expectations of $0.216. The company's Coleman brand travel trailers became the No. 1 sales in the United States as of February 2025, and its market share continued to expand (new and used car market share reached 20% and 11%, respectively). On June 27, a quarterly dividend of $0.125 per share was announced, with an annual dividend yield of approximately 2.98%
$CWH is suitable for short-term traders to capture the rebound opportunities brought by the summer peak demand season and low inventory. It is recommended to buy in the range of $17.69-18.91, with a target of $25 and a stop loss of $12. Long-term investors need to pay attention to the interest rate cut cycle and the company's progress in the field of AI cooling, but be wary of high leverage and macro risks. Closely follow the Q2 financial report in late July to evaluate profitability and inventory dynamics](https://pbs.twimg.com/media/Gu74kLGb0AY1REO.png)
![BlakeSmithJ's tweet photo. 📈 [Today's Stock Forecast]
Stock Code: $NAMM
Buy Price: $10.50-10.96
Target Price: $15-30
Stop Price: $8.50
Holding Period: 20-30 Days
Latest News: $NAMM (traded on the Amsterdam Exchange, code: NAI) is an investment company focusing on the European and American real estate sector. It was established in 2021 and is headquartered in Amsterdam, the Netherlands. The recent stock price soared by more than 300% before the market on July 2, closing at about 9.40 euros (about $10.96), showing strong short-term momentum
Fundamental Overview: The company's 2024 dividend yield is about 4.79%, the market value is about 48.58 million euros, and the price-earnings ratio data is not available (earnings per share is 0.00 euros). Although the real estate market is highly volatile due to macroeconomic factors, $NAMM has shown certain potential through investment in operating real estate companies.
$NAMM is a micro-cap stock with low circulation, sharp fluctuations, and is susceptible to market sentiment and speculation. Lack of stable profit record, high risk of short-term correction, it is recommended to set a strict stop loss](https://pbs.twimg.com/media/Gu71J6UWMAA0hhp.png)
![BlakeSmithJ's tweet photo. 📈 [Today's Stock Forecast]
Stock Code: $PVLA
Purchase Price: $20.42-21.81
Target Price: $30-45
Stop Loss Price: $16
Holding Period: 20-30 Days
$PVLA has recently received investment from institutions such as Strid Group LLC, with a holding value of over $8 million, showing market confidence! Its research and development of rare skin disease treatments is progressing smoothly, and Phase III trial data will be released in Q3, which may be a potential catalyst to push up the stock price. After joining the Russell 2000 Index, ETF fund inflows are expected, which is suitable for mid- and long-term investors!
Risk Warning: Investment is risky, biotech stocks are volatile, and you need to pay attention to clinical trial results and market sentiment. There are risks, so be cautious when entering the market. Please evaluate the investment opportunities of $PVLA based on your own risk tolerance](https://pbs.twimg.com/media/GuxnH3KXMAAiyzQ.png)
![BlakeSmithJ's tweet photo. 📈 [Today's Stock Forecast]
Stock Code: $PVLA
Buy Price: $20.57-21.02
Target Price: $30-45
Stop Loss Price: $17
Holding Period: 20-30 Days
Positive Factors:
Clinical Progress:
The Phase III SELVA trial (microcystic LM) exceeded the 40-person target and will end in June, with results in Q1 2026.
The Phase II TOIVA trial (cutaneous venous malformations) will release results in Q4 2025.
Market Potential: There are approximately 44,553-92,967 LM patients in the United States. If approved, QTORIN can fill the gap in the FDA.
Commercialization: Chief Business Officer Ashley Kline (who once promoted Oxervate to $500 million in sales) joined to strengthen QTORIN's commercialization.
X Sentiment: After Scotiabank's "buy" rating on June 10, X posts reflected optimistic sentiment (Post: No specific content provided).
Risk factors:
High losses: EPS -$7.83 in FY2024, zero revenue, high R&D costs.
Clinical risks: Failures in SELVA and TOIVA trials could cause a stock price crash.
Macro pressures: High Fed rates (4.25%-4.50%) and weak consumption (retail sales down 0.9% in May) affect biotech stocks.
Speculative volatility: Low beta (-0.06) but high recent volatility (8.81%), highly speculative](https://pbs.twimg.com/media/Gusc2ctW0AE4E8N.png)
Olivia
Online
Charles Hatami
@BlakeSmithJ
Long-term investor in stocks and crypto, an optimist, I'll be with you all the way, dedicated to bringing rationality and common sense to the financial world
New York
Joined October 2013
163 Following
3.4K Followers
382 Posts
Pinned Tweet
We are ready to start the $10k to $100k challenge.
All challenges will be held in my WhatsApp group and I will post all my trades for free, including entries and exits. Don't miss the fun
Join us on WhatsApp by clicking on the link: https://t.co/uwT68JCWxO
Reply "9" on my WhatsApp to join for free
$LRHC 🚀🚀🚀🚀🚀
The transaction has ended
Yesterday's closing price was 0.0801 and today's highest price was 0.2332.
Join us now and don't miss tomorrow's trading. I will guide you in the WhatsApp group on when to enter and exit the market to get the most benefits
$LRHC opportunity, buy!
Quantitative rating: Buy
$LRHC has recently become the focus of the market, and its counter-trend rise has caused heated discussions! Latest news: The company announced that it will implement a 1:80 reverse stock split on July 7, and the outstanding shares will be significantly reduced to less than 1 million shares, helping to restore the compliance of the Nasdaq minimum quotation.
Performance highlights: Preliminary unaudited revenue in the first half of 2025 reached US$38.4 million, a year-on-year increase of 19.4%, and the agency team exceeded 3,000 people, showing steady growth.
Strategic expansion: Entering the Spanish and Canary Islands markets, and signing a letter of intent with MiiX Financial Holdings to launch a credit-free mortgage financing plan covering 2,900 agents.
Technical analysis: The stock price rose 33% before the market opened after the reverse stock split news was announced. Low circulation may amplify volatility, and there may be a breakthrough potential in the short term.
Risk warning: Reverse stock splits may bring short-term volatility risks. The company's profitability has not yet stabilized, and it is necessary to be vigilant against speculative speculation and changes in market sentiment
High-quality stock codes with a 10%-30% increase in the next stage are waiting for you!
Click the link to join us: https://t.co/uwT68JCWxO
Famous teachers analyze the stocks you hold 1v1!
Sharing experiences in groups and seeking warmth in groups
No one under 21 allowed to participate in the stock market
📈 [Today's Stock Forecast]
Stock Code: $CWH
Buy Price: $17.23-17.82
Target Price: $25-35
Stop Loss: $12
Holding Period: 20-30 Days
Latest Updates: In the first quarter of 2025, $CWH achieved revenue of $1.41 billion, a year-on-year increase of 3.6%, but failed to meet Wall Street expectations (expected to be $1.45 billion). Non-GAAP loss per share was $0.16, better than analysts' expectations of $0.216. The company's Coleman brand travel trailers became the No. 1 sales in the United States as of February 2025, and its market share continued to expand (new and used car market share reached 20% and 11%, respectively). On June 27, a quarterly dividend of $0.125 per share was announced, with an annual dividend yield of approximately 2.98%
$CWH is suitable for short-term traders to capture the rebound opportunities brought by the summer peak demand season and low inventory. It is recommended to buy in the range of $17.69-18.91, with a target of $25 and a stop loss of $12. Long-term investors need to pay attention to the interest rate cut cycle and the company's progress in the field of AI cooling, but be wary of high leverage and macro risks. Closely follow the Q2 financial report in late July to evaluate profitability and inventory dynamics
![BlakeSmithJ's tweet photo. 📈 [Today's Stock Forecast]
Stock Code: $CWH
Buy Price: $17.23-17.82
Target Price: $25-35
Stop Loss: $12
Holding Period: 20-30 Days
Latest Updates: In the first quarter of 2025, $CWH achieved revenue of $1.41 billion, a year-on-year increase of 3.6%, but failed to meet Wall Street expectations (expected to be $1.45 billion). Non-GAAP loss per share was $0.16, better than analysts' expectations of $0.216. The company's Coleman brand travel trailers became the No. 1 sales in the United States as of February 2025, and its market share continued to expand (new and used car market share reached 20% and 11%, respectively). On June 27, a quarterly dividend of $0.125 per share was announced, with an annual dividend yield of approximately 2.98%
$CWH is suitable for short-term traders to capture the rebound opportunities brought by the summer peak demand season and low inventory. It is recommended to buy in the range of $17.69-18.91, with a target of $25 and a stop loss of $12. Long-term investors need to pay attention to the interest rate cut cycle and the company's progress in the field of AI cooling, but be wary of high leverage and macro risks. Closely follow the Q2 financial report in late July to evaluate profitability and inventory dynamics](https://pbs.twimg.com/media/Gu74l-Ma4AAetXf.png)
📈 [Today's Stock Forecast]
Stock Code: $NAMM
Buy Price: $10.50-10.96
Target Price: $15-30
Stop Price: $8.50
Holding Period: 20-30 Days
Latest News: $NAMM (traded on the Amsterdam Exchange, code: NAI) is an investment company focusing on the European and American real estate sector. It was established in 2021 and is headquartered in Amsterdam, the Netherlands. The recent stock price soared by more than 300% before the market on July 2, closing at about 9.40 euros (about $10.96), showing strong short-term momentum
Fundamental Overview: The company's 2024 dividend yield is about 4.79%, the market value is about 48.58 million euros, and the price-earnings ratio data is not available (earnings per share is 0.00 euros). Although the real estate market is highly volatile due to macroeconomic factors, $NAMM has shown certain potential through investment in operating real estate companies.
$NAMM is a micro-cap stock with low circulation, sharp fluctuations, and is susceptible to market sentiment and speculation. Lack of stable profit record, high risk of short-term correction, it is recommended to set a strict stop loss
![BlakeSmithJ's tweet photo. 📈 [Today's Stock Forecast]
Stock Code: $NAMM
Buy Price: $10.50-10.96
Target Price: $15-30
Stop Price: $8.50
Holding Period: 20-30 Days
Latest News: $NAMM (traded on the Amsterdam Exchange, code: NAI) is an investment company focusing on the European and American real estate sector. It was established in 2021 and is headquartered in Amsterdam, the Netherlands. The recent stock price soared by more than 300% before the market on July 2, closing at about 9.40 euros (about $10.96), showing strong short-term momentum
Fundamental Overview: The company's 2024 dividend yield is about 4.79%, the market value is about 48.58 million euros, and the price-earnings ratio data is not available (earnings per share is 0.00 euros). Although the real estate market is highly volatile due to macroeconomic factors, $NAMM has shown certain potential through investment in operating real estate companies.
$NAMM is a micro-cap stock with low circulation, sharp fluctuations, and is susceptible to market sentiment and speculation. Lack of stable profit record, high risk of short-term correction, it is recommended to set a strict stop loss](https://pbs.twimg.com/media/Gu71On0XgAErtbr.png)
$LRHC opportunity, buy!
Quantitative rating: Buy
$LRHC has recently become the focus of the market, and its counter-trend rise has caused heated discussions! Latest news: The company announced that it will implement a 1:80 reverse stock split on July 7, and the outstanding shares will be significantly reduced to less than 1 million shares, helping to restore the compliance of the Nasdaq minimum quotation.
Performance highlights: Preliminary unaudited revenue in the first half of 2025 reached US$38.4 million, a year-on-year increase of 19.4%, and the agency team exceeded 3,000 people, showing steady growth.
Strategic expansion: Entering the Spanish and Canary Islands markets, and signing a letter of intent with MiiX Financial Holdings to launch a credit-free mortgage financing plan covering 2,900 agents.
Technical analysis: The stock price rose 33% before the market opened after the reverse stock split news was announced. Low circulation may amplify volatility, and there may be a breakthrough potential in the short term.
Risk warning: Reverse stock splits may bring short-term volatility risks. The company's profitability has not yet stabilized, and it is necessary to be vigilant against speculative speculation and changes in market sentiment
We are about to start the $10k to $100k challenge.
All challenges will be held in my WhatsApp group and I will post all my trades for free, including entries and exits. ✅
Join our WhatsApp at https://t.co/QCfkTGMlnw
Reply "9" on my WhatsApp to join for free
$MRT 🚀🚀🚀🚀
$MRT Opportunity, Buy!
Quantitative Rating: Buy
User base growth (2.15 million riders, 314,000 drivers) and AI optimization enhance market competitiveness.
Buyback plan and analyst target price of $5.10 show growth potential.
Regional advantages of the Turkish market may drive long-term development
Short-term traders: Watch for a breakthrough of the $3.00 resistance level, set a stop loss at $2.50 to control risk, and take advantage of the short-term momentum of AI optimization and user growth.
Long-term investors: Wait for Q2 2025 financial report (expected on August 14) to confirm profitability and growth trends, $2.50-$2.80 is a better entry point.
Risk management: It is recommended to diversify investments and pay close attention to trading volume and Turkish market dynamics
📈 [Today's Stock Forecast]
Stock Code: $CWH
Buy Price: $18.69-18.91
Target Price: $25-35
Stop Loss Price: $12
Holding Period: 20-30 Days
After experiencing a trough in early 2025, $CWH has gradually recovered since June. The 9.25% rise on July 1 may indicate the potential to break through $20. However, the long-term trend is still bearish, and the $20-$23 resistance level needs to be broken to confirm the reversal
The technical side shows short-term bullishness. Breaking through $18 on July 1 may push it up to $20-$23, but overbought signals and high volatility indicate the risk of a pullback
![BlakeSmithJ's tweet photo. 📈 [Today's Stock Forecast]
Stock Code: $CWH
Buy Price: $18.69-18.91
Target Price: $25-35
Stop Loss Price: $12
Holding Period: 20-30 Days
After experiencing a trough in early 2025, $CWH has gradually recovered since June. The 9.25% rise on July 1 may indicate the potential to break through $20. However, the long-term trend is still bearish, and the $20-$23 resistance level needs to be broken to confirm the reversal
The technical side shows short-term bullishness. Breaking through $18 on July 1 may push it up to $20-$23, but overbought signals and high volatility indicate the risk of a pullback](https://pbs.twimg.com/media/Gu2wmoIWIAAyTB3.png)
$MRT Opportunity, Buy!
Quantitative Rating: Buy
User base growth (2.15 million riders, 314,000 drivers) and AI optimization enhance market competitiveness.
Buyback plan and analyst target price of $5.10 show growth potential.
Regional advantages of the Turkish market may drive long-term development
Short-term traders: Watch for a breakthrough of the $3.00 resistance level, set a stop loss at $2.50 to control risk, and take advantage of the short-term momentum of AI optimization and user growth.
Long-term investors: Wait for Q2 2025 financial report (expected on August 14) to confirm profitability and growth trends, $2.50-$2.80 is a better entry point.
Risk management: It is recommended to diversify investments and pay close attention to trading volume and Turkish market dynamics
$R 🚀🚀🚀🚀
Opening price: $161.54
Highest price: $171.17
Lowest price: $158.955
Short-term investors: If it breaks through $171.78, you can consider chasing highs, but set a stop loss around $158.955.
Long-term investors: The fundamentals are solid, the logistics industry has a good outlook, and you can hold the stock for a rise, with a target of $180-$190.
It is recommended to pay attention to the Q2 financial report and industry dynamics candlestick chart on July 24 to confirm the sustainability of the upward momentum
$R 🔥🔥🔥🚀🚀🚀
📈 [Today's Stock Forecast]
Stock Code: $PVLA
Purchase Price: $20.42-21.81
Target Price: $30-45
Stop Loss Price: $16
Holding Period: 20-30 Days
$PVLA has recently received investment from institutions such as Strid Group LLC, with a holding value of over $8 million, showing market confidence! Its research and development of rare skin disease treatments is progressing smoothly, and Phase III trial data will be released in Q3, which may be a potential catalyst to push up the stock price. After joining the Russell 2000 Index, ETF fund inflows are expected, which is suitable for mid- and long-term investors!
Risk Warning: Investment is risky, biotech stocks are volatile, and you need to pay attention to clinical trial results and market sentiment. There are risks, so be cautious when entering the market. Please evaluate the investment opportunities of $PVLA based on your own risk tolerance
![BlakeSmithJ's tweet photo. 📈 [Today's Stock Forecast]
Stock Code: $PVLA
Purchase Price: $20.42-21.81
Target Price: $30-45
Stop Loss Price: $16
Holding Period: 20-30 Days
$PVLA has recently received investment from institutions such as Strid Group LLC, with a holding value of over $8 million, showing market confidence! Its research and development of rare skin disease treatments is progressing smoothly, and Phase III trial data will be released in Q3, which may be a potential catalyst to push up the stock price. After joining the Russell 2000 Index, ETF fund inflows are expected, which is suitable for mid- and long-term investors!
Risk Warning: Investment is risky, biotech stocks are volatile, and you need to pay attention to clinical trial results and market sentiment. There are risks, so be cautious when entering the market. Please evaluate the investment opportunities of $PVLA based on your own risk tolerance](https://pbs.twimg.com/media/GuxnK2pWkAA_N41.png)
📈 [Today's Stock Forecast]
Stock Code: $NEON
Purchase Price: $24.81-25.05
Target Price: $30-45
Stop Loss Price: $16
Holding Period: 20-30 Days
Neonode ($NEON) focuses on optical sensing technology, covering high-growth industries such as automobiles, medical care, and aviation. After joining the Russell 2000 Index, institutional investors' attention has increased, and the market performance in the next year is expected. Although there are minor setbacks in the short term due to the postponement of the shareholders' meeting, the long-term growth story remains solid. Deploy $NEON and invest in the future!
![BlakeSmithJ's tweet photo. 📈 [Today's Stock Forecast]
Stock Code: $NEON
Purchase Price: $24.81-25.05
Target Price: $30-45
Stop Loss Price: $16
Holding Period: 20-30 Days
Neonode ($NEON) focuses on optical sensing technology, covering high-growth industries such as automobiles, medical care, and aviation. After joining the Russell 2000 Index, institutional investors' attention has increased, and the market performance in the next year is expected. Although there are minor setbacks in the short term due to the postponement of the shareholders' meeting, the long-term growth story remains solid. Deploy $NEON and invest in the future!](https://pbs.twimg.com/media/Guxk2nQWcAApbA6.png)
I have compiled some recent stock trading information that has seen large gains and will share it for free on WhatsApp, including entry, exit and settlement information. I hope it will be helpful to everyone.
WhatsApp link: ✅ https://t.co/uwT68JCWxO
$INDP 127%
$SGBX 124%
$NVTS 163%
$SYTA 110%
$CYN 582%
Don't miss the next trade!
People under 21 are not allowed to participate in the stock market
Racing towards financial independence one investment at a time, where knowledge is power and risk management is key
Surplus capital finds its true home where risk and reward are one, and the odds are stacked against those who hold still
Risk is just opportunity in disguise for those who dare to trade futures on the open track of the digital highway
Investing is like sailing, you need to know when to anchor and when to ride the wave of uncertainty
Unshackle your assets and let opportunity seep through the cracks of traditional finance
$PVLA stock price rises strongly!
Palvella Therapeutics (NASDAQ: PVLA) has performed well recently, and its stock price continues to rise!
Thanks to the breakthrough progress of its innovative drug QTORIN™ 3.9% rapamycin anhydrous gel in the treatment of rare skin diseases and the positive data of the Phase 3 SELVA trial, the market's confidence in $PVLA continues to rise
📈 [Today's Stock Forecast]
Stock Code: $PVLA
Buy Price: $20.57-21.02
Target Price: $30-45
Stop Loss Price: $17
Holding Period: 20-30 Days
Positive Factors:
Clinical Progress:
The Phase III SELVA trial (microcystic LM) exceeded the 40-person target and will end in June, with results in Q1 2026.
The Phase II TOIVA trial (cutaneous venous malformations) will release results in Q4 2025.
Market Potential: There are approximately 44,553-92,967 LM patients in the United States. If approved, QTORIN can fill the gap in the FDA.
Commercialization: Chief Business Officer Ashley Kline (who once promoted Oxervate to $500 million in sales) joined to strengthen QTORIN's commercialization.
X Sentiment: After Scotiabank's "buy" rating on June 10, X posts reflected optimistic sentiment (Post: No specific content provided).
Risk factors:
High losses: EPS -$7.83 in FY2024, zero revenue, high R&D costs.
Clinical risks: Failures in SELVA and TOIVA trials could cause a stock price crash.
Macro pressures: High Fed rates (4.25%-4.50%) and weak consumption (retail sales down 0.9% in May) affect biotech stocks.
Speculative volatility: Low beta (-0.06) but high recent volatility (8.81%), highly speculative
![BlakeSmithJ's tweet photo. 📈 [Today's Stock Forecast]
Stock Code: $PVLA
Buy Price: $20.57-21.02
Target Price: $30-45
Stop Loss Price: $17
Holding Period: 20-30 Days
Positive Factors:
Clinical Progress:
The Phase III SELVA trial (microcystic LM) exceeded the 40-person target and will end in June, with results in Q1 2026.
The Phase II TOIVA trial (cutaneous venous malformations) will release results in Q4 2025.
Market Potential: There are approximately 44,553-92,967 LM patients in the United States. If approved, QTORIN can fill the gap in the FDA.
Commercialization: Chief Business Officer Ashley Kline (who once promoted Oxervate to $500 million in sales) joined to strengthen QTORIN's commercialization.
X Sentiment: After Scotiabank's "buy" rating on June 10, X posts reflected optimistic sentiment (Post: No specific content provided).
Risk factors:
High losses: EPS -$7.83 in FY2024, zero revenue, high R&D costs.
Clinical risks: Failures in SELVA and TOIVA trials could cause a stock price crash.
Macro pressures: High Fed rates (4.25%-4.50%) and weak consumption (retail sales down 0.9% in May) affect biotech stocks.
Speculative volatility: Low beta (-0.06) but high recent volatility (8.81%), highly speculative](https://pbs.twimg.com/media/Gusc6jab0AAArwD.png)
High-quality stock codes with a 10%-30% increase in the next stage are waiting for you!
Click the link to join us: https://t.co/uwT68JCWxO
Famous teachers analyze the stocks you hold 1v1!
Sharing experiences in groups and seeking warmth in groups
No one under 21 allowed to participate in the stock market
Most Popular Users
Elon Musk 
@elonmusk
241.6M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.1M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
89.8M followers
Taylor Swift
@taylorswift13
83.8M followers
Lady Gaga
@ladygaga
75.3M followers
Virat Kohli
@imvkohli
73.1M followers
Kim Kardashian
@kimkardashian
70.8M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.1M followers
Bill Gates
@billgates
65M followers
Selena Gomez
@selenagomez
62.9M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers